Every 10-Q that Sunshine Biopharma Inc. warrant (SBFMW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SBFMW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBFMW filings page.
Sunshine Biopharma Inc., a Colorado-based pharmaceutical company with generic and OTC operations in Canada and proprietary oncology/antiviral programs, reported second-quarter 2026 results. Q2 2026 revenue was $9,263,687, slightly below $9,410,230 a year earlier, as terminated distribution agreements reduced sales. Gross profit for the quarter was $2,426,682, and the company recorded a net loss of $1,564,048 ($1.15 per share).
For the first six months of 2026, revenue totaled $17,352,452 versus $18,311,571 in 2025, with a net loss of $2,807,917 ($2.95 per share). Operating expenses declined year over year, helped by the absence of a prior-period intangible impairment and lower consulting and R&D costs, partly offset by higher legal fees. Cash and cash equivalents were $13,748,301 at June 30, 2026, and total assets were $33,632,901.
Financing activities in the first half of 2026 provided $7,804,185 of cash, including a May 19, 2026 public offering of 1,200,000 units and warrant exercises. Subsequent to quarter-end, the company established a $4,000,000 at-the-market offering and raised $1,722,555 in net proceeds, received a U.S. patent for its coronavirus protease inhibitors, and continued development of its K1.1 mRNA liver cancer and SBFM-PL4 antiviral candidates.
Sunshine Biopharma reported Q1 2026 sales of $8.1 million, down about 9% from $8.9 million a year earlier, mainly due to the termination of certain distribution agreements. Gross profit was $2.2 million with a margin of 27%, versus $2.7 million and 30.7% in Q1 2025.
The company posted a net loss of $1.24 million, slightly wider than the prior-year loss of $1.18 million, or $(0.25) per share on 4.9 million weighted-average shares. Operating expenses fell to $3.6 million from $4.0 million as accounting, consulting, marketing, office and R&D costs declined, partly offset by higher salaries and legal fees.
Cash and equivalents were $6.9 million at March 31, 2026, with total assets of $27.9 million and no debt beyond lease liabilities. Management estimates current cash and operating cash flows can fund the business for about 17 months while it works to grow Nora Pharma’s Canadian generic drug sales and advance two proprietary programs in liver cancer mRNA and a PLpro inhibitor for SARS coronavirus infections.
Sunshine Biopharma Inc. reported six-month revenue of $18,311,571, up 8.7% year-over-year, with gross profit of $6,153,292 as cost of goods sold fell to 66.4% of sales from 72.0% a year earlier, reflecting improved procurement and pricing.
The company recorded a net loss of $2,950,605 for the six months, driven in part by a $1,061,809 impairment of certain intangible product licenses and higher consulting and salary costs. Operating cash use was $2,987,267 in the period, while cash and equivalents stood at $10,305,320. Financing activities provided $3,948,372 (including registered direct offering net proceeds of $1,828,596 and warrant exercises), and management states existing cash and expected sales are sufficient to fund operations for the next 24 months. The company disclosed a demand letter from its former Nora Pharma president seeking CAD 7,307,025 (~$5.3M), with no accrual recorded. Outstanding potential dilution includes 15,577,965 Series B warrants (as adjusted) and 4,555,945 common shares issued and outstanding.